Tradestie Institutional Equity Comparison Engine

ZLAB vs IMVT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IMVT Overall Edge

IMVT Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunovant, Inc. Common Stock (IMVT) driven by superior Growth & Margin, Options & Structure while ZLAB counters with relative strength in Momentum & Technical. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus IMVT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against IMVT sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZLAB N/M vs IMVT N/M Fwd P/E
Growth & Margin Winner IMVT
Op Margin -63.0% vs 0.0% ยท YoY -6.8% vs +0.0%
Momentum & Technical Winner ZLAB
1Y +9.7% vs +46.0% ยท 52W Pos 60% vs 49%
Options & Structure Winner IMVT
UNCLASSIFIED (58th %ile IV) vs CONSOLIDATION (6th %ile IV)
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
1M Return +2.76%
1Y Return +9.66%
Forward P/E N/M
Unified AI Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
IMVT NASDAQ
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap $7.3B
1M Return +24.6%
1Y Return +45.95%
Forward P/E N/M
Unified AI Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZLAB +9.66% IMVT +45.95% Spread: +36.29 pp (IMVT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZLAB TTM Op. Margin: -63.0% IMVT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs IMVT. Trailing 12-month operating profitability (ZLAB -63.0% vs IMVT 0.0%) and valuation multiples (ZLAB N/M vs IMVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZLAB (3) vs IMVT (5)
Institutional Metric ZLAB IMVT Criterion Row Winner
Market Capitalization Scale $3.0B $7.3B Larger Scale IMVT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -6.8% +0.0% Higher Growth IMVT
Operating Margin (TTM) Profitability -63.0% 0.0% Higher Margin IMVT
Net Profit Margin Profitability -44.9% 0.0% Higher Margin IMVT
Return on Equity (ROE) Capital Efficiency -30.0% -86.5% Higher ROE ZLAB
52-Week Range Position Momentum 60% ($16โ€“$29) 49% ($22โ€“$45) Stronger Trend ZLAB
Beta / 30D Volatility Risk Regime 1.19ฮฒ ยท 78% Vol 1.74ฮฒ ยท 72% Vol Lower Realized Risk IMVT
Unified Institutional Score Composite Signal 47.4 / 100 (HOLD) 39.6 / 100 (SELL) Higher Composite ZLAB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZLAB vs IMVT Buy Guide
ZLAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZLAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IMVT CONSOLIDATION
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live IMVT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZLAB nor IMVT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.